Charles Schwab’s Lifecore Biomedical LFCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$460K Buy
87,650
+7,672
+10% +$38.6K ﹤0.01% 3252
2026
Q1
$298K Sell
79,978
-7,735
-9% -$53.4K ﹤0.01% 3243
2025
Q4
$717K Buy
87,713
+26
+0% +$192 ﹤0.01% 3040
2025
Q3
$645K Sell
87,687
-3
-0% -$23 ﹤0.01% 3088
2025
Q2
$712K Buy
87,690
+8,195
+10% +$55.2K ﹤0.01% 3009
2025
Q1
$560K Buy
79,495
+5,068
+7% +$31.5K ﹤0.01% 3041
2024
Q4
$553K Buy
74,427
+13,922
+23% +$88.9K ﹤0.01% 3115
2024
Q3
$298K Hold
60,505
﹤0.01% 3285
2024
Q2
$310K Buy
60,505
+50,078
+480% +$297K ﹤0.01% 3364
2024
Q1
$55.4K Hold
10,427
﹤0.01% 3359
2023
Q4
$64.5K Hold
10,427
﹤0.01% 3383
2023
Q3
$78.7K Hold
10,427
﹤0.01% 3372
2023
Q2
$101K Sell
10,427
-59,401
-85% -$363K ﹤0.01% 3351
2023
Q1
$264K Hold
69,828
﹤0.01% 3116
2022
Q4
$452K Buy
69,828
+1,836
+3% +$15.1K ﹤0.01% 3026
2022
Q3
$605K Buy
67,992
+1
+0% +$10 ﹤0.01% 2947
2022
Q2
$678K Sell
67,991
-199
-0.3% -$1.97K ﹤0.01% 2941
2022
Q1
$790K Buy
68,190
+1,826
+3% +$20.3K ﹤0.01% 2947
2021
Q4
$737K Hold
66,364
﹤0.01% 3027
2021
Q3
$612K Sell
66,364
-111,531
-63% -$1.21M ﹤0.01% 3070
2021
Q2
$2M Buy
177,895
+5,057
+3% +$58.3K ﹤0.01% 2714
2021
Q1
$1.83M Buy
172,838
+5,174
+3% +$58.2K ﹤0.01% 2687
2020
Q4
$1.82M Sell
167,664
-3,413
-2% -$35.3K ﹤0.01% 2611
2020
Q3
$1.66M Sell
171,077
-15,324
-8% -$146K ﹤0.01% 2556
2020
Q2
$1.48M Buy
186,401
+14,257
+8% +$147K ﹤0.01% 2522
2020
Q1
$1.5M Buy
172,144
+2,279
+1% +$23.7K ﹤0.01% 2382
2019
Q4
$1.92M Buy
169,865
+5,863
+4% +$62.4K ﹤0.01% 2433
2019
Q3
$1.78M Buy
164,002
+4,486
+3% +$48.8K ﹤0.01% 2419
2019
Q2
$1.5M Buy
159,516
+4,760
+3% +$48K ﹤0.01% 2456
2019
Q1
$1.9M Buy
154,756
+2,766
+2% +$33.8K ﹤0.01% 2377
2018
Q4
$1.8M Buy
151,990
+960
+0.6% +$13.2K ﹤0.01% 2367
2018
Q3
$2.17M Buy
151,030
+7,305
+5% +$101K ﹤0.01% 2404
2018
Q2
$2.14M Buy
143,725
+22,475
+19% +$312K ﹤0.01% 2356
2018
Q1
$1.58M Buy
121,250
+3,861
+3% +$50.7K ﹤0.01% 2403
2017
Q4
$1.48M Buy
117,389
+5,148
+5% +$65.1K ﹤0.01% 2405
2017
Q3
$1.45M Buy
112,241
+5,432
+5% +$71.6K ﹤0.01% 2403
2017
Q2
$1.59M Buy
106,809
+589
+0.6% +$8.2K ﹤0.01% 2300
2017
Q1
$1.27M Buy
106,220
+5,301
+5% +$67.1K ﹤0.01% 2353
2016
Q4
$1.39M Buy
100,919
+4,774
+5% +$66.1K ﹤0.01% 2317
2016
Q3
$1.29M Buy
96,145
+4,090
+4% +$49.5K ﹤0.01% 2323
2016
Q2
$991K Sell
92,055
-19,784
-18% -$218K ﹤0.01% 2347
2016
Q1
$1.18M Buy
111,839
+2,474
+2% +$27.2K ﹤0.01% 2275
2015
Q4
$1.29M Buy
109,365
+3,702
+4% +$45.5K ﹤0.01% 2275
2015
Q3
$1.23M Buy
105,663
+23,475
+29% +$311K ﹤0.01% 2308
2015
Q2
$1.19M Buy
82,188
+2,214
+3% +$32K ﹤0.01% 2340
2015
Q1
$1.12M Buy
79,974
+3,132
+4% +$43.3K ﹤0.01% 2327
2014
Q4
$1.06M Buy
76,842
+1,647
+2% +$21.3K ﹤0.01% 2327
2014
Q3
$922K Buy
75,195
+10,675
+17% +$133K ﹤0.01% 2336
2014
Q2
$806K Sell
64,520
-416
-0.6% -$4.9K ﹤0.01% 2417
2014
Q1
$725K Buy
64,936
+1,560
+2% +$17.1K ﹤0.01% 2435
2013
Q4
$769K Buy
63,376
+1,942
+3% +$23.2K ﹤0.01% 2399
2013
Q3
$754K Buy
61,434
+10
+0% +$140 ﹤0.01% 2350
2013
Q2
$851K Buy
+61,424
New +$849K ﹤0.01% 2254

Other funds holding LFCR

Charles Schwab's LFCR Position: Q2 2026 in Review

Charles Schwab increased its Lifecore Biomedical (LFCR) stake by 9.6% in Q2 2026, buying an estimated $38.6K and bringing the position to 87,650 shares worth $460K. The position accounts for ﹤0.01% of the portfolio, ranked #3252.

Charles Schwab first reported a position in LFCR in Q2 2013 and has held it in 53 quarters since. The position peaked at $2.17M in Q3 2018. 99 funds tracked by Wall St. Rank hold LFCR as of Q2 2026.

  • Charles Schwab held 87,650 shares of Lifecore Biomedical worth $460K as of Q2 2026.
  • Charles Schwab bought 7,672 Lifecore Biomedical shares in Q2 2026, an estimated $38.6K.
  • Lifecore Biomedical made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3252 holding.
  • Charles Schwab first reported a position in Lifecore Biomedical in Q2 2013 and has held it in 53 quarters since.
  • Charles Schwab's Lifecore Biomedical position peaked at $2.17M in Q3 2018.
  • 99 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.